PAION to Host Research & Development Day In NYC

PAION AG will host a Research & Development (R&D) day event in NYC: "How can the time-window of thrombolysis In stroke be safely expended?" on Friday November 10, beginning at 12:00 PM Eastern Time. The program will be moderated by PAION’s CEO Wolfgang Soehngen. An updated schedule of the day, with topics and speakers, will be available at www.paion.de. Investors and other interested parties may attend this event and RSVP by sending an email to tfechtner@troutgroup.com or by calling Thomas Fechtner from The Trout Group at (212) 477-9007 x31. In addition, you can access this meeting by visiting the Company's Web site at www.paion.de for a simultaneous web cast of the presentations. If you are unable to participate during the live web cast, the event will be archived on the PAION Web site. Speakers at this event will include: - Dr. Wolfgang SoehngenChief Executive Officer PAION, Founder- Professor Karl-Uwe Petersen, Ph.D,Preclinical Department, PAION- Dr. Mariola Soehngen,Chief Medical Officer PAION, Founder- Anthony J. Furlan, M.D.,Medical Director, Department of Neurology, The Cleveland ClinicFoundation, Cleveland, Principal Investigator DIAS-2 USA/Canada- Professor Werner Hacke, Ph.D.,Managing Director, Neurological University Clinic, HeidelbergUniversity, Heidelberg (Germany), Principal Investigator DIAS-2,Europe/Rest of WorldOver Conference Call- Dr. Max Wintermark,Department of Radiology, University of California, San Francisco- Professor Howard A. Rowley, M.D.,Chief of Neurodadiology; Department of Radiology, University ofWisconsin, Madison For additional details, please contact. Dr. Peer Nils Schröder Thomas Fechtner Investor Relations Martinstrasse 10-12, D-52062 Aachen P: +49-(0)241-4453-152 The Trout Group (212) 477-9007 x31 Mail to: investor.relations@paion.de email: tfechtner@troutgroup.com About stroke Stroke is the third leading cause of death in the industrialised world and a leading cause of serious, long-term disability. In the US alone, 700,000 people suffer from a stroke attack each year, and around 20% of them die within four weeks. For the US, the American Stroke Association expects the financial burden of stroke due to in-hospital costs, long-term care programs and productivity losses to be 58 billion dollars in 2006 alone. About Desmoteplase Desmoteplase, the most specific plasminogen activator known today, is a genetically engineered version of a clot-dissolving protein found in the saliva of the vampire bat Desmodus rotundus. Desmoteplase is partnered with Forest Laboratories, Inc. and H. Lundbeck A/S and currently being tested in an international multi-centred Phase III study for the treatment of acute ischaemic stroke between 3 and 9 hours after onset of symptoms. It has received fast-track designation from the U.S. Food and Drug Administration. About PAION PAION is a public biopharmaceutical company based in Aachen, Germany (Frankfurt Stock Exchange, Prime Standard, ISIN DE000A0B65S3). It aims to become a leader in developing and marketing innovative drugs for the treatment of stroke and other thrombotic diseases for which there is a substantial unmet medical need. PAION’s activities are focused on the development of the three drugs Desmoteplase, Enecadin and Solulin. Currently PAION employs more than 75 people.